2019年冠状病毒病(COVID-19)大流行最近证明了对公共卫生的破坏性影响,经济,和人畜共患传染病的社会发展,病毒从动物身上跳来跳去感染人类。由于病毒具有穿越物种屏障的潜力,对家畜和近人动物的传染性病原体循环进行监测是必不可少的,因为它们可能是潜在的水库。光学生物传感器,主要基于表面等离子体共振(SPR),已经广泛展示了它提供直接、无标签,和定量生物分析具有优异的灵敏度和可靠性。这种生物传感器技术可以为兽医领域提供强大的工具,可能有助于监测感染传播。我们已经实施了一种多靶标COVID-19血清学等离子体生物传感器,用于快速检测和筛查常见的欧洲家畜。多靶标血清学生物传感器测定能够检测针对S和N病毒抗原产生的总SARS-CoV-2抗体(IgGIgM)。使用低体积血清样品(<20μL,1:10稀释),达到49.6ngmL-1的检测限。已经对仓鼠进行了完整的验证,狗,和猫血清样本(N=75,包括37份COVID-19阳性样本和38份阴性样本)。生物传感器表现出优异的诊断灵敏度(100%)和良好的特异性(71.4%),可用于将来在兽医环境中的应用。此外,生物传感器技术集成到一个紧凑的,便携式,和用户友好的设备,非常适合即时测试。这项研究将我们的等离子体生物传感器定位为动物样本中COVID-19血清学的替代和可靠的诊断工具,扩大等离子体技术在兽医保健和动物研究中分散分析的适用性。
The coronavirus disease 2019 (COVID-19) pandemic recently demonstrated the devastating impact on public health, economy, and social development of zoonotic infectious diseases, whereby viruses jump from animals to infect humans. Due to this potential of viruses to cross the species barrier, the surveillance of infectious pathogens circulation in domestic and close-to-human animals is indispensable, as they could be potential reservoirs. Optical biosensors, mainly those based on Surface Plasmon Resonance (SPR), have widely demonstrated its ability for providing direct, label-free, and quantitative bioanalysis with excellent sensitivity and reliability. This biosensor technology can provide a powerful tool to the veterinary field, potentially being helpful for the monitoring of the infection spread. We have implemented a multi-target COVID-19 serology plasmonic biosensor for the rapid testing and screening of common European domestic animals. The multi-target serological biosensor assay enables the detection of total SARS-CoV-2 antibodies (IgG + IgM) generated towards both S and N viral antigens. The analysis is performed in less than 15 min with a low-volume serum sample (<20 μL, 1:10 dilution), reaching a limit of detection of 49.6 ng mL-1. A complete validation has been carried out with hamster, dog, and cat sera samples (N = 75, including 37 COVID-19-positive and 38 negative samples). The biosensor exhibits an excellent diagnostic sensitivity (100 %) and good specificity (71.4 %) for future application in veterinary settings. Furthermore, the biosensor technology is integrated into a compact, portable, and user-friendly device, well-suited for point-of-care testing. This study positions our plasmonic biosensor as an alternative and reliable diagnostic tool for COVID-19 serology in animal samples, expanding the applicability of plasmonic technologies for decentralized analysis in veterinary healthcare and animal research.